Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Alerts
  • Advertising/recruitment
  • Subscribe
  • Contact
  • Current Issue
  • Past Issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • 100th Anniversary of Insulin's Discovery (Jan 2021)
    • Hypoxia-inducible factors in disease pathophysiology and therapeutics (Oct 2020)
    • Latency in Infectious Disease (Jul 2020)
    • Immunotherapy in Hematological Cancers (Apr 2020)
    • Big Data's Future in Medicine (Feb 2020)
    • Mechanisms Underlying the Metabolic Syndrome (Oct 2019)
    • Reparative Immunology (Jul 2019)
    • View all review series ...
  • Viewpoint
  • Collections
    • Recently published
    • In-Press Preview
    • Commentaries
    • Concise Communication
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • Recently published
  • In-Press Preview
  • Commentaries
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Alerts
  • Advertising/recruitment
  • Subscribe
  • Contact
How does leptin restore euglycemia in insulin-deficient diabetes?
Douglas Oberlin, Christoph Buettner
Douglas Oberlin, Christoph Buettner
Published January 23, 2017
Citation Information: J Clin Invest. 2017;127(2):450-453. https://doi.org/10.1172/JCI91880.
View: Text | PDF
Commentary

How does leptin restore euglycemia in insulin-deficient diabetes?

  • Text
  • PDF
Abstract

Insulin replacement is the cornerstone of type 1 diabetes (T1D) treatment; however, glycemic control remains a challenge. Leptin has been shown to effectively restore euglycemia in rodent models of T1D; however, the mechanism or mechanisms by which leptin exerts glycemic control are unclear. In this issue of the JCI, Perry and colleagues provide evidence that suppression of lipolysis is a key facet of leptin-mediated restoration of euglycemia. However, more work remains to be done to fully understand the antidiabetic mechanisms of leptin.

Authors

Douglas Oberlin, Christoph Buettner

×

Figure 1

Model proposed by Perry et al. in this issue to explain the antidiabetic effects of leptin.

Options: View larger image (or click on image) Download as PowerPoint
Model proposed by Perry et al. in this issue to explain the antidiabetic...
Leptin restrains the activity of the HPA axis in T1D, reducing circulating corticosterone, which lowers lipolysis in adipose tissue. As of yet it remains unclear in what tissue and cell type GCs exert these lipolytic effects. Restrained lipolysis results in lower NEFAs and glycerol delivery to the liver, reducing gluconeogenesis and ketogenesis and thereby reversing hyperglycemia and DKA. PEPCK, phosphoenolpyruvate carboxykinase; G3P, glyceraldehyde 3-phosphate; HSL, hormone-sensitive lipase; PC, pyruvate carboxylase; βox, β oxidation.
Follow JCI:
Copyright © 2021 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts